JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

Blood. 2009 Feb 19;113(8):1866-8. doi: 10.1182/blood-2008-11-190975.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Graft vs Tumor Effect
  • Humans
  • Immunotherapy, Adoptive*
  • Janus Kinase 2 / genetics*
  • Middle Aged
  • Point Mutation
  • Primary Myelofibrosis / physiopathology*
  • Primary Myelofibrosis / therapy*
  • Remission Induction
  • Salvage Therapy
  • Stem Cell Transplantation*
  • Transplantation, Homologous

Substances

  • JAK2 protein, human
  • Janus Kinase 2